MBX Biosciences, Inc. Proceeds from Sale and Maturity of Marketable Securities
MBX Biosciences, Inc. (MBX) reported Proceeds from Sale and Maturity of Marketable Securities of $141.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $84.00M, a 14.88% increase year-over-year.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $57.50M, a 0.61% increase year-over-year.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $76.25M, a 276.54% increase year-over-year.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $61.35M, a 127.22% increase year-over-year.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $267.87M, a 235.89% increase from fiscal 2024.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $79.75M, a 141.67% increase from fiscal 2023.
- MBX Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $33.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $84.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $141.50M 10-Q · filed 2026-08-06 | $217.75M derived: sum of 3 quarters · filed 2026-08-06 | $279.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $57.50M 10-Q · filed 2026-05-07 | $133.75M derived: sum of 2 quarters · filed 2026-05-07 | $195.10M derived: sum of 3 quarters · filed 2026-05-07 | $268.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $76.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $137.60M derived: sum of 2 quarters · filed 2026-03-12 | $210.72M derived: sum of 3 quarters · filed 2026-08-06 | $267.87M 10-K · filed 2026-03-12 |
| 2025-09-30 | $61.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $134.47M derived: sum of 2 quarters · filed 2026-08-06 | $191.62M 10-Q · filed 2025-11-06 | $211.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $73.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $130.27M 10-Q · filed 2026-08-06 | $150.52M derived: sum of 3 quarters · filed 2026-08-06 | $177.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $57.15M 10-Q · filed 2026-05-07 | $77.40M derived: sum of 2 quarters · filed 2026-05-07 | $104.40M derived: sum of 3 quarters · filed 2026-05-07 | $112.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $47.25M derived: sum of 2 quarters · filed 2026-03-12 | $55.50M derived: sum of 3 quarters · filed 2026-03-12 | $79.75M 10-K · filed 2026-03-12 |
| 2024-09-30 | $27.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $35.25M derived: sum of 2 quarters · filed 2025-11-06 | $59.50M 10-Q · filed 2025-11-06 | $64.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $32.50M 10-Q · filed 2025-08-07 | $37.50M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $24.25M 10-Q · filed 2025-05-12 | $29.25M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $33.00M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $28.00M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |